Hyderabad, India, 6th June 2011:
Bharat Biotech announced the price of
ROTAVAC® expects India’s licensure during 2014 and WHO Prequalification in 2015 for supply to UN agencies
ROTAVAC® India’s first indigenously developed Rotavirus Vaccine. The vaccine will be sold to global public markets, Governments worldwide including UN procurement agencies at a price of US $ 1. Bharat Biotech hopes its new vaccine will help prevent part of the ~ 500,000 child deaths each year caused due to rotavirus diarrhea and improve access to better, affordable rotavirus vaccines.
The vaccine is currently undergoing Phase III clinical development for safety and efficacy in 8000 subjects, one of the largest such clinical trial ever conducted in India. According to CDC estimates, rotavirus causes approximately 352,000–592,000 deaths each year (median, 440,000 deaths) in children <5 years of age.
Offering rotavirus vaccines at US $1 price is a reaffirmation of our commitment to make vaccines affordable globally
– Dr. Krishna Ella, CMD, Bharat Biotech
Making the announcement Dr. Krishna Ella, thanked his technical and commercial teams for a decade of diligent efforts in delivering a world class product. Dr. Ella says,that the key to our success of bringing down cost of vaccine is our novel concepts in vaccine development and innovative manufacturing processes with public health in mind.
Bharat Biotech strongly backs the initiative by GAVI to make vaccines affordable and available for countries worldwide. The rotavirus vaccine development project is a public-private partnership project between the Company and the Dept of Biotechnology Govt of India, Gates Foundation, Program for Appropriate Technologies in Health, Centers for Disease Control, USA, National Institutes of Health NIAID USA, Society for Applied Studies, Translational Health Sciences Technology Institute, Indian Institute of Science, All India Institute of Medical Sciences, and Stanford University.